GT Biopharma Shares Resume Trade
Save time and jump to the most important pieces.
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G - GT Biopharma, Inc. (0000109657) (Subject)
BRISBANE, Calif., Feb. 18, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced the appointment of Manu Ohri, who joins the Company as its Chief Financial Officer (CFO) effective immediately. Mr. Ohri, an accomplished accounting and finance executive brings to GT Biopharma over 25 years of management, finance and public accounting experience in working with Boar
BEVERLY HILLS, Calif., Nov. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary Tri-specific natural killer (NK) cell engager, TriKE® platform, today announced a restructuring of its executive management team. Mr. Anthony Cataldo, Chairman and Chief Executive Officer and Mr. Michael Handelman, Chief Financial Officer will both pursue other interests. The Board has appointed Dr. Gregory Berk as interim CEO, and Dr. Gavin Choy as acting CFO. Michael Breen has assumed the role of Executive Chairman of the Board, Chair of the Audit Committee and will ove
BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D., to the position of Chief Medical Officer. Dr. Berk has served as a Director on GT Biopharma's Board since November 2020, and resigns that post in conjunction with his appointment. The Company is also pleased to announce that Jeffrey S. Mi
GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H 2025GTB-5550 Phase 1 dose escalation basket trial initiation expected in 2025 evaluating multiple solid tumor types, including prostate, breast, head and neck, ovarian, lung, liver, and GIGTB-7550 TriKE® targets CD19 and is in preclinical development for the treatment of Lupus and other autoimmune indicationsCash of approximately $6.5 million as of September 30, 2024, anticipated to be sufficient to fund operations into Q2 2025 SAN FRANCISCO, CALIFORNIA, Nov. 14, 2024 (GLOBE NEWSWIR
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Dr. Jeffrey Miller, MD1, from the University of Minnesota Medical School2 and GT Biopharma's Consulting Senior Medical Director, will participate in a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York, NY. Company management will also
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced it will host a virtual KOL event on Thursday, October 10, 2024 at 12:00 PM ET. To register, click here. The event will feature Jeffrey Miller, MD1 and Mark Juckett, MD from the University of Minnesota Medical School2, who will give an overview of the NK cell therapy landscape, discuss current limitations and provide perspective on the future direction of the field as it expands into exciting
Believe Urgent Change is Needed at Research Solutions to Address Underperformance, Poor Operational Execution, and Lack of Accountability Highlight that Since Roy Olivier Became Chief Executive Officer, Research Solutions' Share Price Has Declined More than 20% THOUSAND OAKS, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Peter Derycz, Bristol Investment Fund Ltd. ("Bristol Fund") and certain of Bristol Fund's affiliates (collectively, the "Group"), who collectively beneficially own approximately 20% of Research Solutions, Inc.'s (NASDAQ:RSSS) outstanding shares, today issued an open letter from Mr. Derycz to RSSS shareholders regarding why change is needed at RSSS and the Group's intention t
BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer will be hosting a Management Update Conference call on Tuesday, November 30th at 4:30PM Eastern Time. To join the live webcast of the call and view the accom
BEVERLY HILLS, Calif., Aug. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE®) protein biologic technology platform, today provided a general business update of events in the second quarter ending June 30, 2021. "I am pleased with the corporate and clinical development milestones that GT Biopharma continues to achieve throughout the first half of 2021," said Anthony J. Catal
8-K - GT Biopharma, Inc. (0000109657) (Filer)
10-Q - GT Biopharma, Inc. (0000109657) (Filer)
8-K - GT Biopharma, Inc. (0000109657) (Filer)
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025GTB-5550 Phase 1 dose escalation basket trial initiation expected in 2025 evaluating GTB-5550 in six solid tumor cancers, including prostate, breast, head and neck, ovarian, lung, and GICash runway anticipated to be sufficient to fund operations into 2025
Gainers IGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 21.96% to $1.05. The company's market cap stands at $153.8 million. MultiPlan (NYSE:MPLN) shares rose 18.57% to $0.64. The company's market cap stands at $415.4 million. Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 14.61% to $2.98. The company's market cap stands at $7.4 million. TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 12.79% to $1.41. The company's market cap stands at $9.3 million. Indaptus Therapeutics (NASDAQ:INDP) shares moved upward
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by 84.3% to $2.34 during Tuesday's regular session. The market value of their outstanding shares is at $10.2 million. Genelux (NASDAQ:GNLX) shares increased by 28.6% to $5.53. The company's market cap stands at $149.2 million. Novo Integrated Sciences (NASDAQ:NVOS) shares moved upwards by 24.55% to $0.54. The market value of their outstanding shares is at $10.3 million. Bionomics (NASDAQ:BNOX) shares rose 23.93% to $1.14. The company's market cap stands at $12.1 million. Xylo Technologies (NASDAQ:XYLO) shares rose 21.98% to $2.33. The market value of their outstanding shares is at $4.4 million. Accelerate Diagnostics (NASDAQ
4 - GT Biopharma, Inc. (0000109657) (Issuer)
3 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
HC Wainwright & Co. initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00
B. Riley Securities initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $21.00
ROTH Capital initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00